StockData
Atrium Therapeutics, Inc. logo

Atrium Therapeutics, Inc. (RNA) stock

RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.48+0.05 (+0.78%)

Close on Nov 17, 2026Market cap $110.85MP/E –Yield –

Atrium Therapeutics EPS

Diluted earnings per share is net income divided by the share count including options and convertible securities.

Quarterly eps

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$0.25–
Q2 FY2026Jun 30, 2026-$1.18–
Q1 FY2026Mar 31, 2026-$0.97–
Q3 FY2025Sep 30, 2025$0.00–
Q2 FY2025Jun 30, 2025-$0.75–
Q1 FY2025Mar 31, 2025-$0.44–

More Atrium Therapeutics figures

See a number that looks wrong?